Sichuan Haisco Pharmaceutical Co. Ltd. has developed pyrazinone derivatives acting as protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors. They are reported to be useful for the treatment of cancer.
Sichuan Haisco Pharmaceutical Co. Ltd. has described N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of cancer.
Sichuan Haisco Pharmaceutical Co. Ltd. has identified phosphodiesterase PDE3 and phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
Sichuan Haisco Pharmaceutical Co. Ltd. has disclosed AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of diabetic neuropathy and postherpetic neuralgia.
Sichuan Haisco Pharmaceutical Co. Ltd. has synthesized selective estrogen receptor degradation inducers (SERDs) reported to be useful for the treatment of cancer.
Sichuan Haisco Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently bonded to an EGFR (HER1; erbB1) targeting moiety through a linker reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
